Association of albumin to non-high-density lipoprotein cholesterol ratio with mortality in peritoneal dialysis patients

References

• Marckmann P. Nutritional status of patients on hemodialysis and peritoneal dialysis. Clin Nephrol. 1988;29(2):1–10.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815–822. doi: 10.1016/S0140-6736(12)60033-6.
   PubMed Web of Science ®Google Scholar
• Teehan BP, Schleifer CR, Brown JM, et al. Urea kinetic analysis and clinical outcome on CAPD. A five year longitudinal study. Adv Perit Dial. 1990;6:181–185.
   PubMedGoogle Scholar
• Rocco MV, Jordan JR, Burkart JM. The efficacy number as a predictor of morbidity and mortality in peritoneal dialysis patients. J Am Soc Nephrol. 1993;4(5):1184–1191. doi: 10.1681/ASN.V451184.
   PubMed Web of Science ®Google Scholar
• Keshaviah PR, Nolph KD, Moore HL, et al. Lean body mass estimation by creatinine kinetics. J Am Soc Nephrol. 1994;4(7):1475–1485. doi: 10.1681/ASN.V471475.
   PubMed Web of Science ®Google Scholar
• Kinney R, Centers for Medicare and Medicaid Services. 2005 Annual report: ESRD clinical performance measures project. Am J Kidney Dis. 2006;48(2): s1–106. doi: 10.1053/j.ajkd.2006.07.015.
   PubMedGoogle Scholar
• Mehrotra R, Duong U, Jiwakanon S, et al. Serum albumin as a predictor of mortality in peritoneal dialysis: comparisons with hemodialysis. Am J Kidney Dis. 2011;58(3):418–428. doi: 10.1053/j.ajkd.2011.03.018.
   PubMed Web of Science ®Google Scholar
• Jagadeswaran D, Indhumathi E, Hemamalini AJ, et al. Inflammation and nutritional status assessment by malnutrition inflammation score and its outcome in pre-dialysis chronic kidney disease patients. Clin Nutr. 2019;38(1):341–347. doi: 10.1016/j.clnu.2018.01.001.
   PubMed Web of Science ®Google Scholar
• de Mutsert R, Grootendorst DC, Indemans F, et al. Association between serum albumin and mortality in dialysis patients is partly explained by inflammation, and not by malnutrition. J Ren Nutr. 2009;19(2):127–135. doi: 10.1053/j.jrn.2008.08.003.
   PubMed Web of Science ®Google Scholar
• Desmeules S, Arcand-Bossé JF, Bergeron J, et al. Nonfasting non-high-density lipoprotein cholesterol is adequate for lipid management in hemodialysis patients. Am J Kidney Dis. 2005;45(6):1067–1072. doi: 10.1053/j.ajkd.2005.03.002.
   PubMed Web of Science ®Google Scholar
• Wanner C, Krane V. Non-high-density lipoprotein cholesterol: a target of lipid-lowering in dialysis patients. Am J Kidney Dis. 2003;41(3):S72–S75. doi: 10.1053/ajkd.2003.50089.
   PubMed Web of Science ®Google Scholar
• Verbeek R, Hovingh GK, Boekholdt SM. Non-high-density lipoprotein cholesterol: current status as cardiovascular marker. Curr Opin Lipidol. 2015;26(6):502–510. doi: 10.1097/MOL.0000000000000237.
   PubMed Web of Science ®Google Scholar
• Shoji T. Serum lipids and prevention of atherosclerotic cardiovascular events in hemodialysis patients. Clin Exp Nephrol. 2014;18(2):257–260. doi: 10.1007/s10157-013-0871-z.
   PubMed Web of Science ®Google Scholar
• Quispe R, Manalac RJ, Faridi KF, et al. Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: the very large database of lipids-4 (VLDL-4) study. Atherosclerosis. 2015;242(1):243–250. doi: 10.1016/j.atherosclerosis.2015.06.057.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294(3):326–333. doi: 10.1001/jama.294.3.326.
   PubMed Web of Science ®Google Scholar
• Pischon T, Girman CJ, Sacks FM, et al. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112(22):3375–3383. doi: 10.1161/CIRCULATIONAHA.104.532499.
   PubMed Web of Science ®Google Scholar
• Liu J, Sempos C, Donahue RP, et al. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care. 2005;28(8):1916–1921. doi: 10.2337/diacare.28.8.1916.
   PubMed Web of Science ®Google Scholar
• Lu W, Resnick HE, Jablonski KA, et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care. 2003;26(1):16–23. doi: 10.2337/diacare.26.1.16.
   PubMed Web of Science ®Google Scholar
• Tsoupras A, Lordan R, Zabetakis I. Inflammation, not cholesterol, is a cause of chronic disease. Nutrients. 2018;10(5):604. doi: 10.3390/nu10050604.
   PubMed Web of Science ®Google Scholar
• Erlinger TP, Miller ER, 3rd, Charleston J, et al. Inflammation modifies the effects of a reduced-fat low-cholesterol diet on lipids: results from the DASH-sodium trial. Circulation. 2003;108(2):150–154. doi: 10.1161/01.CIR.0000080288.30567.86.
   PubMed Web of Science ®Google Scholar
• Khovidhunkit W, Memon RA, Feingold KR, et al. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis. 2000;(1813):S462–S72. doi: 10.1086/315611.
   PubMedGoogle Scholar
• Don BR, Kaysen G. Serum albumin: relationship to inflammation and nutrition. Semin Dial. 2004;17(6):432–437. doi: 10.1111/j.0894-0959.2004.17603.x.
   PubMed Web of Science ®Google Scholar
• Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: Pathogenesis and clinical significance. JPEN J Parenter Enteral Nutr. 2019;43(2):181–193. doi: 10.1002/jpen.1451.
   PubMed Web of Science ®Google Scholar
• Weinstock RS, Goldberg RB, Guyton JR, et al. Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes. J Clin Lipidol. 2008;2(1):25–35. doi: 10.1016/j.jacl.2008.01.001.
   PubMed Web of Science ®Google Scholar
• Baralić M, Spasojević I, Miljuš G, et al. Albumin at the intersection between antioxidant and pro-oxidant in patients on peritoneal dialysis. Free Radic Biol Med. 2022;187:105–112. doi: 10.1016/j.freeradbiomed.2022.05.019.
   PubMed Web of Science ®Google Scholar
• Kjeldsen EW, Nordestgaard LT, Frikke-Schmidt R. HDL cholesterol and non-cardiovascular disease: a narrative review. Int J Mol Sci. 2021;22(9):4547. doi: 10.3390/ijms22094547.
   PubMed Web of Science ®Google Scholar
• David N, Churchill D, Taylor W, et al. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. Canada-USA (CANUSA) peritoneal dialysis study group. J Am Soc Nephrol. 1996;7:198–207.
   PubMed Web of Science ®Google Scholar
• Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15(5):458–482. doi: 10.1016/s0272-6386(12)70364-5.
   PubMed Web of Science ®Google Scholar
• Ho L, Wang H, Chiang C, et al. Malnutrition-inflammation score independently determined cardiovascular and infection risk in peritoneal dialysis patients. Blood Purif. 2010;30(1):16–24. doi: 10.1159/000316682.
   PubMed Web of Science ®Google Scholar
• Burkart JM. Effect of peritoneal dialysis prescription and peritoneal membrane transport characteristics on nutritional status. Perit Dial Int. 1995;15(5):20–37. doi: 10.1177/089686089501505S03.
   Web of Science ®Google Scholar
• Sezer S, Tutal E, Arat Z, et al. Peritoneal transport sta­tus influence on atherosclerosis/inflammation in CAPD patients. J Ren Nutr. 2005;15(4):427–434 doi: 10.1053/j.jrn.2005.07.007.
   PubMed Web of Science ®Google Scholar
• Yu J, Xia X, Lin T, et al. Non-high-density lipoprotein cholesterol and mortality among peritoneal dialysis patients. J Clin Lipidol. 2021;15(5):732–742. doi: 10.1016/j.jacl.2021.06.005.
   PubMed Web of Science ®Google Scholar
• Wang A, Li Y, Zhou L, et al. Non-HDL-C/HDL-C ratio is associated with carotid plaque stability in general population: a cross-sectional study. Front Neurol. 2022;13:875134. doi: 10.3389/fneur.2022.875134.
   PubMed Web of Science ®Google Scholar
• Wu X, Meng J, Zhou L, et al. Albumin to total cholesterol ratio and mortality in peritoneal dialysis. Front Med (Lausanne). 2022;9(9):896443. doi: 10.3389/fmed.2022.896443.
   PubMedGoogle Scholar
• Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004;291(4):451–459. doi: 10.1001/jama.291.4.451.
   PubMed Web of Science ®Google Scholar
• Zyga S, Christopoulou G, Malliarou M. Malnutrition-inflammation-atherosclerosis syndrome in patients with end-stage renal disease. J Ren Care. 2011;37(1):12–15. doi: 10.1111/j.1755-6686.2011.00201.x.
   PubMedGoogle Scholar
• Harris KP, Wheeler DC, Chong CC. Continuous ambulatory peritoneal dialysis. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney Int. 2002;61(4):1469–1474. doi: 10.1046/j.1523-1755.2002.00262.x.
   PubMed Web of Science ®Google Scholar
• Saltissi D, Morgan C, Rigby RJ, et al. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis. 2002;39(2):283–290. doi: 10.1053/ajkd.2002.30547.
   PubMed Web of Science ®Google Scholar
• Navaneethan SD, Nigwekar SU, Perkovic V, et al. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev. 2009;15(9):CD004289. doi: 10.1002/14651858.CD004289.pub3.
   Google Scholar
• Diepeveen SH, Verhoeven GW, Van Der Palen J, et al. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial. J Int Med. 2005;257(5):438–445. doi: 10.1111/j.1365-2796.2005.01484.x.
   PubMed Web of Science ®Google Scholar
• Stegmayr BG, Brännström M, Bucht S, et al. Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scand J Urol Nephrol. 2005;39(6):489–497. doi: 10.1080/00365590500329304.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zeng X, Fu P, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients. Cochrane Database Syst Rev. 2014;2014(6):CD009120. doi: 10.1002/14651858.CD009120.pub2.
   PubMedGoogle Scholar
• Han SH, Kang EW, Yoon SJ, et al. Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis. Nephrol Dial Transplant. 2011;26(11):3722–3728. doi: 10.1093/ndt/gfr108.
   PubMed Web of Science ®Google Scholar
• Mugendi GA, Mutua FM, Natale P, et al. Calcium channel blockers for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2020;10(10):CD011064. doi: 10.1002/14651858.CD011064.pub2.
   PubMedGoogle Scholar